Literature DB >> 7679206

Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM.

U Korthäuer1, D Graf, H W Mages, F Brière, M Padayachee, S Malcolm, A G Ugazio, L D Notarangelo, R J Levinsky, R A Kroczek.   

Abstract

X chromosome-linked immunodeficiency with hyper-IgM (HIGM1, MIM number 308230) is a rare disorder characterized by recurrent bacterial infections, very low or absent IgG, IgA and IgE, and normal to increased IgM and IgD serum levels. HIGM1 has been suggested to result from ineffective T-cell help for B cells. We and others have identified a novel, TNF-related activation protein (TRAP) that is exclusively expressed on the surface of stimulated T cells. TRAP, a type II transmembrane protein of M(r) 33,000, is the physiological ligand for CD40 (refs 5-8). Crosslinking of CD40 on B cells induces, in the presence of lymphokines, immunoglobulin class switching from IgM to IgG, IgA or IgE. Mapping of the TRAP gene to the X-chromosomal location q26.3-q27.1 (ref. 6) suggested a causal relationship to HIGM1, which had previously been assigned to Xq26 (refs 12-14). Here we present evidence that point mutations in the TRAP gene give rise to nonfunctional or defective expression of TRAP on the surface of T cells in patients with HIGM1. The resultant failure of TRAP to interact with CD40 on functionally intact B cells is responsible for the observed immunoglobulin isotype defect in HIGM1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679206     DOI: 10.1038/361539a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  180 in total

1.  Cloning, expression and biological function of the bovine CD40 homologue: role in B-lymphocyte growth and differentiation in cattle.

Authors:  A Hirano; W C Brown; D M Estes
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  A polymorphic CD40 ligand (CD154) molecule mediates CD40-dependent signalling but interferes with the ability of soluble CD40 to functionally block CD154:CD40 interactions.

Authors:  B Barnhart; G S Ford; A Bhushan; C Song; L R Covey
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

3.  Prevalence of SAP gene defects in male patients diagnosed with common variable immunodeficiency.

Authors:  D Eastwood; K C Gilmour; K Nistala; C Meaney; H Chapel; Z Sherrell; A D Webster; E G Davies; A Jones; H B Gaspar
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

4.  Non-functional immunoglobulin G transcripts in a case of hyper-immunoglobulin M syndrome similar to type 4.

Authors:  John M Darlow; Alex M Farrell; David I Stott
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

Review 5.  Pitfalls of "hyper"-IgM syndrome: a new CD40 ligand mutation in the presence of low IgM levels. A case report and a critical review of the literature.

Authors:  A Heinold; B Hanebeck; V Daniel; J Heyder; T H Tran; B Döhler; J Greil; F-M Müller
Journal:  Infection       Date:  2010-10-28       Impact factor: 3.553

6.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.

Authors:  M Koshy; D Berger; M K Crow
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 7.  Therapeutic potential for blockade of the CD40 ligand, gp39.

Authors:  J E Buhlmann; R J Noelle
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

8.  T cell clones from an X-linked hyper-immunoglobulin (IgM) patient induce IgE synthesis in vitro despite expression of nonfunctional CD40 ligand.

Authors:  P Life; J F Gauchat; V Schnuriger; S Estoppey; G Mazzei; A Durandy; A Fischer; J Y Bonnefoy
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

9.  Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome.

Authors:  K Agematsu; H Nagumo; K Shinozaki; S Hokibara; K Yasui; K Terada; N Kawamura; T Toba; S Nonoyama; H D Ochs; A Komiyama
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

10.  Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation.

Authors:  M Teresa de la Morena; David Leonard; Troy R Torgerson; Otavio Cabral-Marques; Mary Slatter; Asghar Aghamohammadi; Sharat Chandra; Luis Murguia-Favela; Francisco A Bonilla; Maria Kanariou; Rongras Damrongwatanasuk; Caroline Y Kuo; Christopher C Dvorak; Isabelle Meyts; Karin Chen; Lisa Kobrynski; Neena Kapoor; Darko Richter; Daniela DiGiovanni; Fatima Dhalla; Evangelia Farmaki; Carsten Speckmann; Teresa Español; Anna Shcherbina; Imelda Celine Hanson; Jiri Litzman; John M Routes; Melanie Wong; Ramsay Fuleihan; Suranjith L Seneviratne; Trudy N Small; Ales Janda; Liliana Bezrodnik; Reinhard Seger; Andrea Gomez Raccio; J David M Edgar; Janet Chou; Jordan K Abbott; Joris van Montfrans; Luis Ignacio González-Granado; Nancy Bunin; Necil Kutukculer; Paul Gray; Gisela Seminario; Srdjan Pasic; Victor Aquino; Christian Wysocki; Hassan Abolhassani; Morna Dorsey; Charlotte Cunningham-Rundles; Alan P Knutsen; John Sleasman; Beatriz Tavares Costa Carvalho; Antonio Condino-Neto; Eyal Grunebaum; Helen Chapel; Hans D Ochs; Alexandra Filipovich; Mort Cowan; Andrew Gennery; Andrew Cant; Luigi D Notarangelo; Chaim M Roifman
Journal:  J Allergy Clin Immunol       Date:  2016-09-30       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.